Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: A population-based cohort study

Cheng E. Chee, Aneel Arjun Ashrani, Randolph Stuart Marks, Tanya M. Petterson, Kent R Bailey, L. Joseph Melton, John A. Heit

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Active cancer is themajor predictor of venous thromboembolism(VTE) recurrence, but further stratification of recurrence risk is uncertain. In a population-based cohort study of all Olmsted County, Minnesota, residents with active cancer-related incident VTE during the 35-year period from1966 to 2000 who survived 1 day or longer, we estimated VTE recurrence, bleeding on anticoagulant therapy, and survival and tested cancer and noncancer characteristics and secondary prophylaxis as predictors of VTE recurrence and bleeding, using Cox proportional hazardsmodeling. Of 477 patients, 139 developed recurrentVTE over the course of 1533 person-years of follow-up. The adjusted 10-year cumulative VTE recurrence rate was 28.6%. The adjusted 90-day cumulative incidence of major bleeding on anticoagulation was 1.9%. Survival was significantly worse for patients with cancer who had recurrent VTE (particularly pulmonary embolism) and with bleeding on anticoagulation. In a multivariable model, brain, lung, and ovarian cancer; myeloproliferative or myelodysplastic disorders; stage IV pancreatic cancer; other stage IV cancer; cancer stage progression; and leg paresis were associated with an increased hazard, and warfarin therapy was associated with a reduced hazard, of recurrent VTE. Recurrence rates were significantly higher for cancer patients with 1 or more vs no predictors of recurrence, suggesting these predictors may be useful for stratifying recurrence risk.

Original languageEnglish (US)
Pages (from-to)3972-3978
Number of pages7
JournalBlood
Volume123
Issue number25
DOIs
StatePublished - Jun 19 2014

Fingerprint

Venous Thromboembolism
Hazards
Cohort Studies
Brain models
Hemorrhage
Recurrence
Warfarin
Anticoagulants
Population
Neoplasms
Survival
Paresis
Pancreatic Neoplasms
Pulmonary Embolism
Brain Neoplasms
Ovarian Neoplasms
Lung Neoplasms
Leg
Incidence
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Predictors of venous thromboembolism recurrence and bleeding among active cancer patients : A population-based cohort study. / Chee, Cheng E.; Ashrani, Aneel Arjun; Marks, Randolph Stuart; Petterson, Tanya M.; Bailey, Kent R; Melton, L. Joseph; Heit, John A.

In: Blood, Vol. 123, No. 25, 19.06.2014, p. 3972-3978.

Research output: Contribution to journalArticle

@article{b0aa57c28e214dbf970c3244d209129e,
title = "Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: A population-based cohort study",
abstract = "Active cancer is themajor predictor of venous thromboembolism(VTE) recurrence, but further stratification of recurrence risk is uncertain. In a population-based cohort study of all Olmsted County, Minnesota, residents with active cancer-related incident VTE during the 35-year period from1966 to 2000 who survived 1 day or longer, we estimated VTE recurrence, bleeding on anticoagulant therapy, and survival and tested cancer and noncancer characteristics and secondary prophylaxis as predictors of VTE recurrence and bleeding, using Cox proportional hazardsmodeling. Of 477 patients, 139 developed recurrentVTE over the course of 1533 person-years of follow-up. The adjusted 10-year cumulative VTE recurrence rate was 28.6{\%}. The adjusted 90-day cumulative incidence of major bleeding on anticoagulation was 1.9{\%}. Survival was significantly worse for patients with cancer who had recurrent VTE (particularly pulmonary embolism) and with bleeding on anticoagulation. In a multivariable model, brain, lung, and ovarian cancer; myeloproliferative or myelodysplastic disorders; stage IV pancreatic cancer; other stage IV cancer; cancer stage progression; and leg paresis were associated with an increased hazard, and warfarin therapy was associated with a reduced hazard, of recurrent VTE. Recurrence rates were significantly higher for cancer patients with 1 or more vs no predictors of recurrence, suggesting these predictors may be useful for stratifying recurrence risk.",
author = "Chee, {Cheng E.} and Ashrani, {Aneel Arjun} and Marks, {Randolph Stuart} and Petterson, {Tanya M.} and Bailey, {Kent R} and Melton, {L. Joseph} and Heit, {John A.}",
year = "2014",
month = "6",
day = "19",
doi = "10.1182/blood-2014-01-549733",
language = "English (US)",
volume = "123",
pages = "3972--3978",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "25",

}

TY - JOUR

T1 - Predictors of venous thromboembolism recurrence and bleeding among active cancer patients

T2 - A population-based cohort study

AU - Chee, Cheng E.

AU - Ashrani, Aneel Arjun

AU - Marks, Randolph Stuart

AU - Petterson, Tanya M.

AU - Bailey, Kent R

AU - Melton, L. Joseph

AU - Heit, John A.

PY - 2014/6/19

Y1 - 2014/6/19

N2 - Active cancer is themajor predictor of venous thromboembolism(VTE) recurrence, but further stratification of recurrence risk is uncertain. In a population-based cohort study of all Olmsted County, Minnesota, residents with active cancer-related incident VTE during the 35-year period from1966 to 2000 who survived 1 day or longer, we estimated VTE recurrence, bleeding on anticoagulant therapy, and survival and tested cancer and noncancer characteristics and secondary prophylaxis as predictors of VTE recurrence and bleeding, using Cox proportional hazardsmodeling. Of 477 patients, 139 developed recurrentVTE over the course of 1533 person-years of follow-up. The adjusted 10-year cumulative VTE recurrence rate was 28.6%. The adjusted 90-day cumulative incidence of major bleeding on anticoagulation was 1.9%. Survival was significantly worse for patients with cancer who had recurrent VTE (particularly pulmonary embolism) and with bleeding on anticoagulation. In a multivariable model, brain, lung, and ovarian cancer; myeloproliferative or myelodysplastic disorders; stage IV pancreatic cancer; other stage IV cancer; cancer stage progression; and leg paresis were associated with an increased hazard, and warfarin therapy was associated with a reduced hazard, of recurrent VTE. Recurrence rates were significantly higher for cancer patients with 1 or more vs no predictors of recurrence, suggesting these predictors may be useful for stratifying recurrence risk.

AB - Active cancer is themajor predictor of venous thromboembolism(VTE) recurrence, but further stratification of recurrence risk is uncertain. In a population-based cohort study of all Olmsted County, Minnesota, residents with active cancer-related incident VTE during the 35-year period from1966 to 2000 who survived 1 day or longer, we estimated VTE recurrence, bleeding on anticoagulant therapy, and survival and tested cancer and noncancer characteristics and secondary prophylaxis as predictors of VTE recurrence and bleeding, using Cox proportional hazardsmodeling. Of 477 patients, 139 developed recurrentVTE over the course of 1533 person-years of follow-up. The adjusted 10-year cumulative VTE recurrence rate was 28.6%. The adjusted 90-day cumulative incidence of major bleeding on anticoagulation was 1.9%. Survival was significantly worse for patients with cancer who had recurrent VTE (particularly pulmonary embolism) and with bleeding on anticoagulation. In a multivariable model, brain, lung, and ovarian cancer; myeloproliferative or myelodysplastic disorders; stage IV pancreatic cancer; other stage IV cancer; cancer stage progression; and leg paresis were associated with an increased hazard, and warfarin therapy was associated with a reduced hazard, of recurrent VTE. Recurrence rates were significantly higher for cancer patients with 1 or more vs no predictors of recurrence, suggesting these predictors may be useful for stratifying recurrence risk.

UR - http://www.scopus.com/inward/record.url?scp=84902668499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902668499&partnerID=8YFLogxK

U2 - 10.1182/blood-2014-01-549733

DO - 10.1182/blood-2014-01-549733

M3 - Article

C2 - 24782507

AN - SCOPUS:84902668499

VL - 123

SP - 3972

EP - 3978

JO - Blood

JF - Blood

SN - 0006-4971

IS - 25

ER -